JPH08505369A - 精製されたtsh製剤、その製法、及び、tsh受容体検定用tshトレーサー製造での及びtsh受容体検定でのその用途 - Google Patents
精製されたtsh製剤、その製法、及び、tsh受容体検定用tshトレーサー製造での及びtsh受容体検定でのその用途Info
- Publication number
- JPH08505369A JPH08505369A JP6510683A JP51068394A JPH08505369A JP H08505369 A JPH08505369 A JP H08505369A JP 6510683 A JP6510683 A JP 6510683A JP 51068394 A JP51068394 A JP 51068394A JP H08505369 A JPH08505369 A JP H08505369A
- Authority
- JP
- Japan
- Prior art keywords
- tsh
- formulation
- tracer
- antibody
- purification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003911 Thyrotropin Receptors Human genes 0.000 title claims abstract description 61
- 108090000253 Thyrotropin Receptors Proteins 0.000 title claims abstract description 61
- 238000003556 assay Methods 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims description 78
- 238000009472 formulation Methods 0.000 title claims description 76
- 239000000700 radioactive tracer Substances 0.000 claims abstract description 62
- 241000283690 Bos taurus Species 0.000 claims abstract description 50
- 238000000746 purification Methods 0.000 claims abstract description 40
- 230000004071 biological effect Effects 0.000 claims abstract description 35
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 29
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 29
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 20
- 230000002378 acidificating effect Effects 0.000 claims abstract description 11
- 238000004255 ion exchange chromatography Methods 0.000 claims abstract description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000741 silica gel Substances 0.000 claims abstract description 6
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 6
- 239000004952 Polyamide Substances 0.000 claims abstract description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 5
- 229920002647 polyamide Polymers 0.000 claims abstract description 5
- 230000027455 binding Effects 0.000 claims description 34
- 238000005259 measurement Methods 0.000 claims description 16
- 239000000499 gel Substances 0.000 claims description 12
- 230000009870 specific binding Effects 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 8
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 8
- 238000002372 labelling Methods 0.000 claims description 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- 239000003729 cation exchange resin Substances 0.000 claims description 6
- 239000013060 biological fluid Substances 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims 5
- 238000005341 cation exchange Methods 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000001768 cations Chemical class 0.000 abstract description 3
- 102000011923 Thyrotropin Human genes 0.000 abstract description 2
- 108010061174 Thyrotropin Proteins 0.000 abstract description 2
- 229960000874 thyrotropin Drugs 0.000 abstract description 2
- 230000001748 thyrotropin Effects 0.000 abstract description 2
- 102000005962 receptors Human genes 0.000 description 28
- 108020003175 receptors Proteins 0.000 description 28
- 230000000694 effects Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 9
- 229910052740 iodine Inorganic materials 0.000 description 9
- 239000011630 iodine Substances 0.000 description 9
- 210000001685 thyroid gland Anatomy 0.000 description 9
- 239000000463 material Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 5
- 238000011033 desalting Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000005495 thyroid hormone Substances 0.000 description 5
- 229940036555 thyroid hormone Drugs 0.000 description 5
- 229940034208 thyroxine Drugs 0.000 description 5
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 5
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 4
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 238000001261 affinity purification Methods 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000007973 glycine-HCl buffer Substances 0.000 description 2
- 239000000960 hypophysis hormone Substances 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000270281 Coluber constrictor Species 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- OQZCSNDVOWYALR-UHFFFAOYSA-N flurochloridone Chemical compound FC(F)(F)C1=CC=CC(N2C(C(Cl)C(CCl)C2)=O)=C1 OQZCSNDVOWYALR-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.粗製ウシTSH(チロトロビン)の精製によって得られ、直接の放射性ヨ ウ素化によってTSH受容体検定法用の放射性ヨウ素化TSHトレーサーに変換 可能で、タンパク質mg当たり40 IU TSHを越える生物活性をもち、かつ抗TSH 抗体カラムでのアフィニティ・クロマトグラフィと、それに続く末端カルボキシ ル基を持ち、ポリアミド被覆されたシリカゲルに基づく弱酸性陽イオン交換装置 でのイオン交換クロマトグラフィによる市販粗製ウシTSHの精製によって得ら れる、TSH製剤。 2.タンパク質mg当たり約55 IU TSHの生物活性をもった、請求項1に記載の TSH製剤。 3.以下の請求項4〜7のいずれか一に記載の方法によって得られる、請求項 1項又は第2項のいずれかに記載のTSH製剤。 4. (1)抗TSH抗体アフィニティゲル上で粗製のウシTSHを処理し、精製 TSH調製物の溶離液を回収し; (2)アフィニティ・クロマトグラフィによって精製された、段階(1)か ら得られた該TSH溶離液を、弱酸性陽イオン交換樹脂上のイオン交換クロマト グラフィによって処理し; (3)段階(2)の溶離液のうち、280nmで吸光する分 画を回収し;そして (4)段階(2){段階(3)}から得られる溶離液分画を凍結乾燥する; 以上の段階を含む、タンパク質mg当たり約40 IU TSHを越える生物活性をもった 、請求項1〜3項の何れか一に記載のTSH製剤の製法。 5.アフィニティ・クロマトグラフィによる粗製ウシTSHの精製が、抗TS H抗体アフィニティカラムの助けによって行なわれることを特徴とし、該カラム が (a)過ヨウ素酸ナトリウムによりモノクローナル抗TSH抗体を酸化し; (b)脱塩カラムにより低分子量成分から該酸化抗体を分離し; (c)タンパク質カップリングゲルで該脱塩された酸化抗体を培養し;そし て (d)該結合した抗TSH抗体を有するゲルを慣用のカラムへ移すこと; によって得られ、全段階を通じて慣用の緩衝液と洗浄液が使用される、請求項4 に記載の方法。 6.段階(2)のイオン交換クロマトグラフィが、末端カルボキシル基をもち ポリアミド被覆されたシリカゲルに基づく弱酸性陽イオン交換樹脂を使用して実 施される、請求項4項又は第5のいずれかに記載の方法。 7.モノクローナル抗体5405(メディックス社、フィ ンランド国カウニアイネン)と同一の、又は類似した結合性状をもった抗TSH 抗体が、精製段階(1)の抗TSH抗体アフィニティカラムの製造用抗体として 使用される、請求項4〜6項のいずれかに一に記載の方法。 8.段階(1)から得られる溶離液が希釈されて、段階(2)に直接に使用さ れ、また段階(2)から得られる溶離液が固体二酸化炭素の温度に直ちに冷却さ れる、請求項4〜7のいずれか一に記載の方法。 9.これまで知られた任意の標識分子での標識化によって、TSH受容体検定 法用のトレーサーを製造のための、請求項1〜3項ののいずれかに記載のTSH 製剤又は請求項4〜8のいずれかに記載の方法からの生成物の用途。 10.放射性ヨウ素化によって得られるトレーサー製剤をアフィニティ・クロ マトグラフィにより後で更に精製することなしに、上記TSH製剤のそれ自体知 られた直接的放射性ヨウ素化によって、TSH受容体検定用の放射性ヨウ素化さ れたTSHトレーサーをつくるための、請求項9に記載のTSH製剤の用途。 11.30%以上の特異的結合をもった放射性ヨウ素化TSHトレーサーをつく るための、請求項10に記載のTSH製剤の用途。 12.放射性ヨウ素化の全放射能収率が45〜50%である、請求項10又は11 に記載のTSH製剤の用途。 13.TSH受容体自己抗体を測定するためのTSH受容体検定法でのトレー サーとしての、このTSH製剤のその後の直接的放射性ヨウ素化によって得られ る放射性ヨウ素化されたTSH製剤の形の、請求項1〜4項ののいずれか一に記 載のTSH製剤又は請求項5〜8のいずれかに記載の方法の生成物の用途。 14.生物体液中のTSH受容体自己抗体の測定に要し、かつB0>12,500 dp mの値に適用可能な計数時間が1分の領域内にある量で、該トレーサーがTSH 放射性受容体検定に使用される、請求項13に記載の用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4237430.8 | 1992-11-05 | ||
DE4237430A DE4237430C1 (de) | 1992-11-05 | 1992-11-05 | Aufgereinigtes TSH-Präparat, Verfahren zu seiner Herstellung und seine Verwendung zur Herstellung von TSH-Tracern für TSH-Rezeptorassays und in TSH-Rezeptorassays |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08505369A true JPH08505369A (ja) | 1996-06-11 |
JP2835781B2 JP2835781B2 (ja) | 1998-12-14 |
Family
ID=6472210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6510683A Expired - Fee Related JP2835781B2 (ja) | 1992-11-05 | 1993-10-27 | Tshトレーサーの製造方法 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0668775B1 (ja) |
JP (1) | JP2835781B2 (ja) |
AT (1) | ATE162948T1 (ja) |
AU (1) | AU669953B2 (ja) |
CA (1) | CA2148690A1 (ja) |
DE (2) | DE4237430C1 (ja) |
FI (1) | FI952140A (ja) |
WO (1) | WO1994009814A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010536934A (ja) * | 2007-08-31 | 2010-12-02 | ナームローゼ・フエンノートチヤツプ・オルガノン | Tsh受容体拮抗性のテトラヒドロキノリン化合物 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7238338B1 (en) | 2001-06-22 | 2007-07-03 | Triumf | System and method for the large scale labeling of compounds with radiohalogens |
ITRM20030214A1 (it) * | 2003-05-05 | 2004-11-06 | Univ Roma | Ormone stimolante la tiroide (tsh) radiomarcato e suo uso |
CN102050875B (zh) * | 2010-12-10 | 2013-05-29 | 天津市协和医药科技有限公司 | 一种促甲状腺素受体的提取及纯化方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4357310A (en) * | 1980-08-08 | 1982-11-02 | Baxter Travenol Laboratories, Inc. | Method and composition for reducing the nonspecific binding of radioiodinated protein hormones |
US4474891A (en) * | 1982-06-10 | 1984-10-02 | Warren Michelle P | Mini-iodinated polypeptide hormone tracer and method for its use |
GB8510177D0 (en) * | 1985-04-22 | 1985-05-30 | Public Health Laborotory Servi | Isolating pituitary glycoprotein hormones |
JPH04108397A (ja) * | 1990-08-27 | 1992-04-09 | Internatl Reagents Corp | モノクローナル抗体及びそれを用いたtsh測定法 |
-
1992
- 1992-11-05 DE DE4237430A patent/DE4237430C1/de not_active Expired - Fee Related
-
1993
- 1993-10-27 EP EP93923561A patent/EP0668775B1/en not_active Expired - Lifetime
- 1993-10-27 AU AU53387/94A patent/AU669953B2/en not_active Ceased
- 1993-10-27 DE DE69316911T patent/DE69316911T2/de not_active Expired - Lifetime
- 1993-10-27 AT AT93923561T patent/ATE162948T1/de active
- 1993-10-27 WO PCT/EP1993/002980 patent/WO1994009814A1/en active IP Right Grant
- 1993-10-27 CA CA002148690A patent/CA2148690A1/en not_active Abandoned
- 1993-10-27 JP JP6510683A patent/JP2835781B2/ja not_active Expired - Fee Related
-
1995
- 1995-05-04 FI FI952140A patent/FI952140A/fi not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010536934A (ja) * | 2007-08-31 | 2010-12-02 | ナームローゼ・フエンノートチヤツプ・オルガノン | Tsh受容体拮抗性のテトラヒドロキノリン化合物 |
Also Published As
Publication number | Publication date |
---|---|
EP0668775A1 (en) | 1995-08-30 |
FI952140A0 (fi) | 1995-05-04 |
JP2835781B2 (ja) | 1998-12-14 |
DE69316911T2 (de) | 1998-05-28 |
ATE162948T1 (de) | 1998-02-15 |
AU5338794A (en) | 1994-05-24 |
WO1994009814A1 (en) | 1994-05-11 |
EP0668775B1 (en) | 1998-02-04 |
DE69316911D1 (de) | 1998-03-12 |
FI952140A (fi) | 1995-05-04 |
DE4237430C1 (de) | 1994-03-17 |
CA2148690A1 (en) | 1994-05-11 |
AU669953B2 (en) | 1996-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4312853A (en) | Radioimmunological determination of procollagen (type III) and procollagen peptide (type III) | |
Linsley et al. | Detection of larger polypeptides structurally and functionally related to type I transforming growth factor. | |
CA1235118A (en) | Assay for qualitatively and/or quantitatively measuring hlh or hcg body fluids and reagents therefor | |
WO1983004312A1 (en) | Monoclonal antibody mixtures and use thereof for enhanced sensitivity immunoassays | |
US4264571A (en) | Radioimmunoassay of thymosin α1 | |
O'Riordan et al. | Isolation and chemical properties of porcine parathyroid hormone | |
Birken et al. | reparation and Characterization of an Improved β-COOH-Terminal Immunogen for Generation of Specific and Sensitive Antisera to Human Chorionic Gonadotropin | |
US4407965A (en) | Process for preparing antibody | |
JPH0428718B2 (ja) | ||
JP2599096B2 (ja) | 遊離リガンドアッセイのための組成物 | |
Goldstein | Radioimmunoassay for thymopoietin | |
US4339427A (en) | Radioimmunoassay of thymosinα | |
Buckley et al. | A sensitive radioimmunoassay for corticotropin using a fully biologically active125I-labeled ligand | |
JP2729159B2 (ja) | ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法 | |
US4543340A (en) | Radioimmunoassay of thymosin β4 | |
Fahrenkrug et al. | Production and evaluation of antibodies for radioimmunoassay of secretin | |
JPS6259783B2 (ja) | ||
WO1990002759A1 (en) | Improvements relating to peptides | |
Gold et al. | Physicochemical approach to the purification of human α1-fetoprotein from the ascites fluid of a hepatoma-bearing patient | |
JP2835781B2 (ja) | Tshトレーサーの製造方法 | |
US4096237A (en) | Immunoassay for β-endorphin | |
JPS6311626B2 (ja) | ||
JP2925479B2 (ja) | 肺小細胞癌検出薬及びその使用 | |
SCARPACE et al. | Preparation and immunological characteristics of biologically active radioiodinated human calcitonin | |
JPH03163095A (ja) | ヒト神経成長因子の部分ペプチド、抗体およびその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071009 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081009 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081009 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091009 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101009 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101009 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111009 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111009 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121009 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121009 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131009 Year of fee payment: 15 |
|
LAPS | Cancellation because of no payment of annual fees |